Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Cancer Causes Control. 2019 Sep;30(9):909-922. doi: 10.1007/s10552-019-01204-z. Epub 2019 Jul 12.
Childhood cancer survivors are at increased risk of developing subsequent malignant neoplasms (SMNs). We compared survival and clinical characteristics of survivors with SMNs (sarcoma, breast cancer, or melanoma) and a population-based sample of similar first malignant neoplasm (FMN) patients.
We assembled three case series of solid SMNs observed in a cohort of 5-year Dutch childhood cancer survivors diagnosed 1963-2001 and followed until 2014: sarcoma (n = 45), female breast cancer (n = 41), and melanoma (n = 17). Each SMN patient was sex-, age-, and calendar year-matched to 10 FMN patients in the population-based Netherlands Cancer Registry. We compared clinical and histopathological characteristics by Fisher's exact tests and survival by multivariable Cox regression and competing risk regression analyses.
Among sarcoma-SMN patients, overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.23-2.87] and sarcoma-specific mortality (HR 1.91, 95% CI 1.16-3.13) were significantly worse compared to sarcoma-FMN patients (foremost for soft-tissue sarcoma), with 15-year survival rates of 30.8% and 61.6%, respectively. Overall survival did not significantly differ for breast-SMN versus breast-FMN patients (HR 1.14, 95% CI 0.54-2.37), nor for melanoma-SMN versus melanoma-FMN patients (HR 0.71, 95% CI 0.10-5.00). No significant differences in tumor characteristics were observed between breast-SMN and breast-FMN patients. Breast-SMN patients were treated more often with mastectomy without radiotherapy/chemotherapy compared to breast-FMN patients (17.1% vs. 5.6%).
Survival of sarcoma-SMN patients is worse than sarcoma-FMN patients. Although survival and tumor characteristics appear similar for breast-SMN and breast-FMN patients, treatment differs; breast-SMN patients less often receive breast-conserving therapy. Larger studies are necessary to substantiate these exploratory findings.
儿童癌症幸存者发生继发性恶性肿瘤(SMN)的风险增加。我们比较了患有 SMN(肉瘤、乳腺癌或黑色素瘤)的幸存者和基于人群的相似首发恶性肿瘤(FMN)患者的生存和临床特征。
我们汇集了荷兰儿童癌症幸存者队列中观察到的三种固体 SMN 病例系列,这些幸存者于 1963-2001 年诊断,并随访至 2014 年:肉瘤(n=45)、女性乳腺癌(n=41)和黑色素瘤(n=17)。每个 SMN 患者均与基于人群的荷兰癌症登记处的 10 名 FMN 患者按性别、年龄和日历年份匹配。我们通过 Fisher 精确检验比较临床和组织病理学特征,并通过多变量 Cox 回归和竞争风险回归分析比较生存。
在肉瘤-SMN 患者中,总体生存率(危险比 [HR] 1.88,95%置信区间 [CI] 1.23-2.87)和肉瘤特异性死亡率(HR 1.91,95%CI 1.16-3.13)明显差于肉瘤-FMN 患者(主要是软组织肉瘤),15 年生存率分别为 30.8%和 61.6%。乳腺癌-SMN 患者与乳腺癌-FMN 患者的总体生存率无显著差异(HR 1.14,95%CI 0.54-2.37),黑色素瘤-SMN 患者与黑色素瘤-FMN 患者的总体生存率也无显著差异(HR 0.71,95%CI 0.10-5.00)。乳腺癌-SMN 患者和乳腺癌-FMN 患者的肿瘤特征无显著差异。与乳腺癌-FMN 患者相比,乳腺癌-SMN 患者更常接受乳房切除术而不接受放疗/化疗(17.1% vs. 5.6%)。
肉瘤-SMN 患者的生存率差于肉瘤-FMN 患者。尽管乳腺癌-SMN 患者和乳腺癌-FMN 患者的生存和肿瘤特征似乎相似,但治疗方法不同;乳腺癌-SMN 患者较少接受保乳治疗。需要更大的研究来证实这些探索性发现。